Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 5,902 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

NCT03836040
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 7:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abraxane and Alimta in Advanced Solid Tumors

NCT00470548
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Abraxane, Alimta
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Response Study of Aerobic Exercise in Older Adults

NCT01129115
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Nonexercise control group, Aerobic Exercise Group 1, Aerobic Exercise Group 2, Aerobic Exercise Group 3
Behavioral
Lead sponsor
Jeff Burns, MD
Other
Eligibility
65 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00112840
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
CCI-779, Bevacizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 23, 2026, 7:31 PM EDT
Active, not recruiting Phase 1 Interventional

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

NCT06125197
View directory record Official record
Conditions
Lung Cancer
Interventions
TILT-123, KEYTRUDA®
Biological
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Newport Beach, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults

NCT01924910
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
250,000 IU cholecalciferol as single, oral dose, Placebo
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 23, 2026, 7:31 PM EDT
Recruiting Phase 3 Interventional

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

NCT05696613
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
SNP-ACTH (1-39) Gel, Rituximab
Drug
Lead sponsor
Cerium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
19
States / cities
Los Angeles, California • San Dimas, California • Tarzana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)

NCT01411774
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, d-cycloserine, Pill placebo
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
St. Petersburg, Florida • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

NCT01599897
View directory record Official record
Conditions
Pulmonary Tuberculosis
Interventions
ID93 + GLA-SE, ID93 alone
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 23, 2026, 7:31 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin

NCT05066113
View directory record Official record
Conditions
Hidradenitis Suppurativa, Healthy Volunteers
Interventions
Radiofrequency-Based treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00397813
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
3
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 23, 2026, 7:31 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

NCT05766748
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Azeliragon
Drug
Lead sponsor
Cantex Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Boca Raton, Florida • Eugene, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Traumatic Brain Injury Peripheral Nerve Study

NCT01588691
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Eon-mini IPG (implantable pulse generator)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Poway, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 23, 2026, 7:31 PM EDT
Active, not recruiting Not applicable Interventional

Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

NCT06192758
View directory record Official record
Conditions
Prostate, Cancer
Interventions
TheraSphere PCa
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
50 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 7:31 PM EDT
Not listed Not applicable Interventional

Internet-Based Interventions for Bipolar Disorder

NCT02106078
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Moderated Discussion Board, Psychoeducation, Interactive Psychosocial Tools
Behavioral
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Proleukin and Rapamune in Type 1 Diabetes

NCT00525889
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
IL-2, Rapamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

NCT03190174
View directory record Official record
Conditions
Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions
Nab-Rapamycin, Nivolumab
Drug · Biological
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors

NCT01128218
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Tumor fluorescence
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 23, 2026, 7:31 PM EDT
Recruiting Phase 1 Interventional

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04243785
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
BTX-A51, Azacitidine
Drug
Lead sponsor
Edgewood Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Duarte, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 23, 2026, 7:31 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

NCT06367738
View directory record Official record
Conditions
Aging
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment of Post-SCI Hypotension

NCT02919917
View directory record Official record
Conditions
Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Hypotension, Cerebral Blood Flow, Blood Pressure, Venous Occlusion Plethysmography
Interventions
Midodrine Hydrochloride
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 23, 2026, 7:31 PM EDT
Terminated Phase 1 Interventional

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

NCT03905889
View directory record Official record
Conditions
Renal Cell Carcinoma Metastatic
Interventions
Abemaciclib, Sunitinib
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 23, 2026, 7:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

NCT05369390
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 23, 2026, 7:31 PM EDT